MORGAN STANLEY PLC/CALL/INCYTE CO./70/0.5/20.09.24 | Market Closed - Börse Stuttgart 17:19:21 28/06/2024 BST | ||
| 0.58 EUR | -4.92% |
|
| Current month | +7.41% | ||
| 1 month | +18.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.58 | -4.92% |
| 27/06/24 | 0.61 | -6.15% |
| 26/06/24 | 0.65 | -19.75% |
| 25/06/24 | 0.81 | -7.95% |
| 24/06/24 | 0.88 | +11.39% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 05:19 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9GR8 |
| ISIN | DE000ME9GR89 |
| Date issued | 01/03/2024 |
| Strike | 70 $ |
| Maturity | 20/09/2024 (82 Days) |
| Parity | 2 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.96 € |
|---|---|
| Lowest since issue | 0.239 € |
| Spread | 0.05 € |
| Spread % | 7.94% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
60.62
USD
Average target price
72.8
USD
Spread / Average Target
+20.09%
- Stock Market
- Warrants
- Warrant
